Philippe C.
- Country
- France
- Department
- Hématologie
Research Overview
- Phase 2 Study on Zanubrutinib and BGB-11417 Efficacy and Tolerance in Previously Treated Waldenström Macroglobulinemia Patients
- Phase 3 Randomized, Double-Blind Study of Brentuximab Vedotin, Lenalidomide, and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Evaluation of Tumor Lysis Syndrome Risk in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax, Obinutuzumab, or Acalabrutinib Combinations
Data & Insights
Has run more than one trial at 28 of 114 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating chronic lymphocytic leukemia (CLL), with particular focus on novel therapeutic approaches and treatment strategies for previously untreated patients.
- CLL Management in Elderly Patients
- Treatment-naïve CLL Interventions
- Tumor Lysis Syndrome Risk Assessment
Their work encompasses evaluation of targeted therapies including venetoclax and acalabrutinib combinations.
Lymphoma Research
The investigator has significant expertise in treating diffuse large B-cell lymphoma (DLBCL), focusing on advanced therapeutic options for relapsed and refractory cases.
- Relapsed/Refractory DLBCL Treatment
- Novel Combination Therapies
- Immunotherapy Applications
Their research includes innovative treatment combinations incorporating brentuximab vedotin, lenalidomide, and rituximab.
Therapeutic Innovation
The investigator explores targeted therapeutic approaches in hematologic malignancies, with emphasis on antibody-drug conjugates and combination treatments.
- Treatment Response Assessment
- Progressive Disease Management
- Novel Drug Development
Their work includes evaluation of zilovertamab vedotin and other emerging therapies in lymphoid malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.